drugset / Trial / NCT07422285

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

NCT07422285

Phase 1 Active not recruiting 405 enrolled Amgen
RandomizedParallel-groupOpen-labelBasic science

Summary

The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.

Timeline

Start
2026-01-16
Primary completion
2026-07-24
Completion
2026-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Evolocumab Monoclonal antibody Subcutaneous

Indications

No indication recorded.